Orange Book Blog

At the intersection of Patent and FDA Law

Pharma News Briefs

FDA Law Blog reported Monday that the proposed follow-on biologics legislation is in serious jeopardy in Congress. Pharmalot had a similar report last Friday.
Meanwhile, European regulators recently granted approval to three new biosimilar drugs, as Patent Docs reports today.
The San Francisco Chronicle recently published a nice article summarizing the debate over generic biotech drugs.
The Business Standard recently reported on incentives for Indian drug companies to develop generic biotech drugs.
Peter Zura’s 271 blog had this interesting post Wednesday on controversy caused by reaction of the Indian generic pharmaceutical industry to patent reform legislation in Congress.
MarketWatch had this article last weekend examining the leveling off of pharmaceutical prices in America.
Par and J&J announced they have settled their generic Ultracet patent litigation: MarketWatch; Patent Docs.
IMPAX announced a district court ruling relating to generic Rilutek: PharmaLive; UPI.